Health Science Journal

  • ISSN: 1108-7366
  • Journal h-index: 61
  • Journal CiteScore: 17.30
  • Journal Impact Factor: 18.23
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • CINAHL Complete
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • EMCare
  • OCLC- WorldCat
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

Covid-19 and T2 Diabetes Mellitus (T2DM): a Dangerous Association

XX Congresso Regionale FADOI CAMPANIA: Non ci siamo mai fermati
Italy 2021

Maffettone A, Rossi F, Di Sarno A, d’Errico T, Italiano G, Scarano F, Parrella R, Fiorentino G, Esposito V, Sangiovanni V and Di Fraia S

UOC Medicina Cardiovascolare e Dismetabolica AO Ospedali dei Colli, Napoli, Italy
UOC Mal. Infettive Ad Indirizzo Respiratorio, AO Ospedali dei Colli, Napoli, Italy
UOC Fisiopatologia E Riabilitaz. Respiratoria, AO Ospedali dei Colli, Napoli, Italy
UOC Mal. Infettive E Medicina Di Genere, AO Ospedali dei Colli, Napoli, Italy
UOC Mal. Infettive E Dell'immunodepresso, AO Ospedali dei Colli, Napoli, Italy
Ambulatorio e DH Di Reumatologia PSI Napoli Est, Asl Napoli 1 Centro, Italy
UOC di Medicina Interna, Azienda Ospedaliera S.Anna e San Sebastiano, Caserta, Italy

Posters & Accepted Abstracts: Health Sci J


Background and Aims: During November 2020 through february 2021 we evaluated how the therapies used in treating Covid-19 patients affected blood glucose control in those with both COVID-19 and T2DM. Materials and Methods: We evaluated 432 inpatients affected with Covid-19 pneumonia and T2DM. 337 were male (78%) and 95 female (22%) with age 70 ± 5 yrs and a HbA1c 9 ± 0.7%. Their at home diabetic therapy, along with antibiotic and steroid therapy was always switched to a basal bolus insulin regimen. Results: The T2DM and Covid-19 in-patients had a BMI 28 ± 3 kg/sm and an average of total insulin daily dosage (TDD) at hospitalization of 54 ± 7 IU/day and at discharge of 77 ± 8 IU/day. At hospitalization we performed an i.v insulin infusion protocol to achieve normal blood glucose values that lasted 48 hrs in 195 pts (45%). The switch to basal bolus insulin therapy was made on the 3rd day of hospitalization. The major amount of insulin was administered before lunch and supper (both covering 40% of TDD) with 20% of TDD at night as basal. The major cause of this increase (40%) of TDD is in part due to the inflammatory state and partly to steroid therapy. We didn’t detect any hypoglycemia. Conclusions: We used an enormous amount of insulin, both iv and on basal bolus regimen to achieve a slightly sufficient blood glucose control. Further evaluation in the use of other antihyperglycemic drugs combined to insulin regimen seems appropriate and necessary.